Figure 2.

Effect of pamidronate exposure on neutrophil function. Experiments were carried out as presented in Figure 1, but with the change that pamidronate was used as the bisphosphonate. (A) In vitro chemotaxis experiments (Zigmond chamber) were performed with PMN pretreated with pamidronate (2.5, 10 or 20 µM). *P < 0.05, significantly different from control. (B) Respiratory burst in pamidronate -treated PMN was quantified using a cytochrome C oxidation assay. *P < 0.05, significantly different from fMLP alone. (C) In vivo recruitment of PMN was quantified in pamidronate-treated mice or carrier (PBS)-treated mice. *P < 0.05, significantly different from PBS. Data shown are means ± SD; n = 3 with three mice per experiment.